Editas Medicine (NASDAQ: EDIT) reviewed 10-14-2020
Market Cap: $2.0 Billion (USD) Share Price: $32.16 (USD)
Shares outstanding: 62,103,649
Cash & cash equivalents: $485.8 M (USD) as of 30 Jun 2020
Debt: None stated on the balance sheet
Insiders: 2.4% Institutional: 291 holders own approx. 76% of the float
Website: editasmedicine.com
Investor Presentations: https://ir.editasmedicine.com/events-and-presentations
CEO: Cynthia Collins HQs: Cambridge, Mass. USA
Editas Medicine is a gene-editing company that seeks to transform the genome editing system (CRISPR/Cas9 and CRISPR/Cpf1) into a pipeline of medicines to treat serious diseases
CRISPR is a pair of biological “scissors” used to modify genetic code
The two discoverers of CRISPR, Emmanuelle Charpentier (France) and Jennifer Doudna (US) recently received the Nobel Prize for Chemistry (Note: they are not Editas employees)
Editas has a variety of early-stage clinical products:
IN Vivo CRISPR medicines:
- EDIT-101 – Leber Congenital Amaurosis 10 (LCA10)
- EDIT-102 – Usher Syndrome 2A (USH2A)
- Neurological diseases
EX Vivo CRISPR medicines:
- EDIT-301 – Sickle Cell
- EDIT-201 – Healthy Donor NK (HDNK) Cells
The company targets ocular diseases, blood diseases, and cancer
Editas reported a loss of $1.12 (USD) for the six months ended 30 Jun 2020
Bottom Line:
- Editas is a dark horse biotech that has a genome editing platform based on more precise and safer CRISPR technology now into both in vivo and ex vivo clinical trials using their advanced pluripotent cell line